Business Context and Reporting Period
This Form 8-K Current Report was filed by Aclarion, Inc. on June 26, 2024. The Company, incorporated in Delaware, is an emerging growth company with its principal executive offices in Broomfield, Colorado. Its common stock and warrants trade on the Nasdaq Stock Market under the symbols ACON and ACONW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a specific corporate event rather than periodic financial performance.
Material Changes
On June 26, 2024, Aclarion, Inc. announced a material development regarding its Nociscan product. The Company secured initial payer coverage from AXA, a private medical insurance provider in the United Kingdom. This coverage applies specifically to the greater London, U.K. area.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future outlook, or a discussion of risks and contingencies beyond the announcement of the new payer agreement. No unusual items were reported in this document.
Investor Verification Checklist
- Verify the specific terms and scope of the Nociscan coverage agreement with AXA.
- Confirm the commercial impact of the greater London area coverage on future revenue projections.
- Review the attached press release (Exhibit 99.1) for additional details on the partnership.